Fertilization promoting peptide (FPP; pGlu-Glu-ProNH 2 ) is a peptide produced by the prostate gland and then secreted into seminal plasma. Recent studies have shown that the addition of FPP to uncapacitated mouse and human sperm suspensions stimulates capacitation as demonstrated by cytological assessment and increased fertilizing/penetrating ability in vitro, hence its name. Interestingly, the addition of FPP also has an effect on capacitated cells, namely inhibition of spontaneous acrosome loss; these spermatozoa retain high fertilizing ability, however, when tested with unfertilized oocytes. Adenosine, which is known to modulate adenylate cyclase activity, has been shown to elicit responses similar to those obtained with FPP in both uncapacitated and capacitated spermatozoa. Because the use of FPP and adenosine simultaneously is more effective than either used individually, it has been proposed that these two molecules interact with different receptors to modulate the adenylate cyclase/cAMP signal transduction pathway. FPP-related peptides have been found to vary in their biological activity in vitro, the most interesting one being Gln-FPP (pGlu-Gln-ProNH 2 ). This peptide, identified in human seminal plasma and possibly produced by men with prostatic dysfunction, had no intrinsic activity itself but was able to competitively inhibit responses to FPP. Finally, very recent evidence suggests that the protein TCP-11, coded for by a mouse ^-complex gene, may be the receptor for FPP. The existence of a human homologue for Tcp-11 suggests that TCP-11 and FPP could well play an important role in human fertility/subfertility. In vitro, FPP's ability to stimulate capacitation might reduce the incidence of delayed fertilization which results in impaired embryonic development and implantation.
Introduction
Fertilization promoting peptide (FPP) is a tripeptide (pyroglutamylglutamylprolineamide; pGlu-Glu-ProNH 2 ) very similar in structure to thyrotrophin-releasing hormone (TRH; pGlu-His-ProNH 2 ) and so is capable of cross-reacting with TRH antibodies. Although TRH-like material was detected immunologically in mammalian prostate glands and semen in the early 1980s (Pekary et al, 1980 (Pekary et al, , 1983 , it was not until 1989 that it was isolated from the rabbit prostate complex, characterized and shown to be distinct from TRH (Cockle et al, 1989) . Subsequent investigations revealed FPP in the prostate glands and/or semen of several other mammalian species, including the human, rabbit and various rodents (Cockle, 1995) .
Given the presence of FPP in human seminal plasma at quite high concentrations for such a small peptide (49.5 ± 10.3 nM, mean ± SEM; Cockle et al, 1994) , a plausible cell type with which it might interact is the spermatozoon. A number of recent studies have provided considerable evidence that FPP can indeed elicit biologically relevant responses in spermatozoa that could be very important for maximizing fertilizing potential in vivo. It is for this reason that the peptide has been called 'fertilization promoting peptide' (Green et al, 1994) .
Effects of FPP on uncapacitated and capacitated spermatozoa
The first studies of FPP were conducted on epididymal mouse spermatozoa because: (i) these cells would not have come into contact with the peptide and (ii) a well-characterized mouse sperm in-vitro capacitation and fertilization system was available for the investigation (Fraser, 1993) . Cells treated with FPP were analysed cytologically for capacitation using chlortetracycline (CTC) fluorescence and functionally using in-vitro fertilization (IVF).
The use of CTC proved crucial to the success of the initial investigations because although FPP was judged to have a stimulatory effect on capacitation, it did not stimulate acrosome loss. Most cytological techniques used to determine the effects of treatment on sperm capacitation only identify acrosome-intact and Figure 1 . Chlortetracycline (CTC) assessment revealed that 50-500 nM fertilization promoting peptide (FPP) significantly stimulated epididymal mouse sperm capacitation during a 40 min incubation in vitro. Data are presented as mean % cells ± SEM (n = 4). D, F pattern, characteristic of uncapacitated, acrosome-intact cells; H, B pattern, characteristic of capacitated, acrosome-intact cells; gl, AR pattern, characteristic of capacitated, acrosome-reacted cells. *P < 0.05, **P < 0.025, ***P < 0.01 compared with control (0 FPP) suspensions (from Green et al, 1994, with permission). acrosome-reacted cells. With CTC, the acrosome-intact category can be subdivided into two on the basis of apparent differences in their functional state, i.e. uncapacitated and capacitated. CTC analysis of spermatozoa from a number of mammalian species has revealed three main patterns of fluorescence on the sperm head: (i) F, with bright fluorescence over the entire head, characteristic of uncapacitated, acrosome-intact cells; (ii) B, with a fluorescence-free dark band in the postacrosomal region, characteristic of capacitated, acrosome-intact cells; and (iii) AR, with dull fluorescence over the head, characteristic of capacitated, acrosome-reacted cells. The relative proportions of cells exhibiting these patterns change as the spermatozoa undergo capacitation and become demonstrably fertile (e.g. Ward and Storey, 1984; Fraser and McDermott, 1992; DasGupta et al, 1993; Fraser et al, 1995; Wang et al, 1995) .
Potentially fertilizing spermatozoa should be those exhibiting the B pattern of CTC fluorescence, since incubation of uncapacitated mouse spermatozoa in the presence of 100 nM FPP for a short time, significantly stimulated capacitation as shown by an increase in the proportion of B pattern cells, but there was no concomitant increase in AR pattern cells (Figure 1 ; Green et al, 1994) . Using an assay other than CTC, we would have concluded that FPP had no bioactivity, but on the basis of the CTC results we predicted that peptide-treated cells would be more fertile in vitro and then were able to confirm this using IVF (Green et al, 1994) . Consistent with this increased fertilizing ability, computer-assisted sperm analysis (CASA) of motility following a short incubation in FPP revealed a significant increase in the proportion of cells expressing parameters related to hyperactivated motility (Green et al, 1996c) .
When human sperm suspensions, prepared using mini-Percoll gradients, were incubated in the presence of FPP and then assessed using CTC, a significant stimulation of capacitation per se (but not of acrosome loss) was observed, consistent with the results obtained using mouse spermatozoa. We postulated that these cells would also be more fertile and tested the proposal using the zona-free hamster oocyte penetration test (HOPT). Since FPP does not induce acrosome loss, FPP-treated cells were exposed to progesterone (5 |Ltg/ml; 15.9 juM) for a short time to trigger the acrosome reaction before adding them to zona-free hamster oocytes. Suspensions treated with FPP + progesterone were significantly more fertile than those treated with only FPP or progesterone or with neither (Green et al, 1996a) .
Since FPP had significant effects on uncapacitated cells, it seemed reasonable to determine whether it had any effect on capacitated cells. Interestingly, the continuous presence of FPP for 120 min (sufficient for capacitation in this system; e.g. Fraser and Duncan, 1993) or its introduction at 120 min significantly inhibited spontaneous acrosome loss, yet left the cells capable of undergoing the acrosome reaction in response to progesterone (Green et al, 1996b) .
This biphasic response to FPP, i.e. stimulatory when used on uncapacitated cells and inhibitory when used on capacitated cells, was similar to the pattern of responses elicited when adenosine effects on adenylate cyclase activity in mouse spermatozoa were evaluated, i.e. enzyme activity was stimulated in uncapacitated but inhibited in capacitated sperm preparations (Stein et al, 1986) . When adenosine was evaluated following the protocols used for FPP, it significantly stimulated capacitation in uncapacitated mouse spermatozoa and significantly inhibited spontaneous acrosome loss in capacitated cells (Green et al., 1996b) . To investigate the possibility that the two molecules were modulating the same pathway but acting via different receptors, FPP + adenosine treatment was assessed. Using optimal concentrations of the two (100 nM FPP + 10 jiM adenosine), there was greater stimulation of capacitation than that observed with either used individually, consistent with them acting on the same pathway. Even more convincing evidence, however, was obtained using low, non-stimulatory concentrations (12.5 nM FPP + 0.1 \\M adenosine): used individually, neither elicited a response but when used together, a significant stimulation of capacitation, slightly greater than that observed with 50 nM FPP, was observed.
Because adenosine, acting via surface receptors, has been shown to stimulate fertilizing ability (Fraser, 1990) and to stimulate the adenylate cyclase activity in uncapacitated mouse spermatozoa (Fraser and Duncan, 1993) , we have proposed that FPP and adenosine are both acting on the adenylate cyclase/cAMP pathway via separate, specific receptors (Green et al, 1996b) . This is consistent with the additive effects observed with FPP + adenosine and also with the recent study reporting that capacitation-dependent increases in tyrosine phosphorylation of a number of proteins are regulated by cAMP and protein kinase A (Visconti et al, 1995a,b) . In addition, Fenichel et al. (1996) have presented data showing that an analogue of adenosine stimulates protein tyrosine phosphorylation in uncapacitated human spermatozoa but can have inhibitory effects on capacitated suspensions. Green et al, 1994 Green et al, , 1996a Fraser et al., 1997a) 
Biological activity of FPP-related peptides
Since FPP clearly elicits biologically important responses in mammalian spermatozoa, the importance of peptide structure was investigated using a range of FPPrelated peptides. TRH and pGlu-Phe-ProNH 2 (identified in human seminal plasma; Khan et al, 1992) proved to have some biological activity, although, when tested at 50 nM, only FPP caused significant stimulation of capacitation in both human (Green et al, 1996a) and mouse (Green et al., 1996b) spermatozoa. All these peptides have a C-terminal amide group, as do many other small biologically active neural and endocrine peptides (e.g. calcitonin, gastrin, corticotrophin releasing hormone, gonadotrophin-releasing hormone; reviewed by Eipper et al, 1992) . The amide group appears to be necessary both for peptide stability and for binding to receptors and its removal usually abolishes activity. When deamidated FPP was investigated at concentrations up to 200 nM, it had no detectable activity on uncapacitated mouse spermatozoa and, when used in conjunction with FPP, it did not inhibit responses to FPP (Fraser et al, 1997a) . It would appear that deamidated FPP does not bind to spermatozoa.
At a physiological pH, FPP would be negatively charged. Three neutral FPPrelated peptides (pGlu-Phe-ProNH 2 , pGlu-Gln-ProNH 2 and pGlu-Glu[OMe]-ProNH 2 ) were evaluated for biological activity in the absence/presence of FPP; each had a different effect on mouse spermatozoa. The first two peptides are of particular interest because they have been identified in human seminal plasma (Khan et al, 1992) As shown earlier, pGlu-Phe-ProNH 2 was slightly stimulatory when used individually; when used simultaneously with FPP, the response observed was that obtained with FPP alone, suggesting that the two peptides bind to the same site. The methyl derivative had no effect when used alone at concentrations up to 200 nM and had no inhibitory effect when used together with FPP, suggesting that the peptide does not bind to sperm cells.
pGlu-Gln-ProNH 2 (Gln-FPP) differed from the other two neutral peptides. Used alone, it elicited no responses; used simultaneously with FPP it was able to competitively inhibit responses to FPP in a concentration-dependent manner (Figure 2A ) but it did not inhibit responses to adenosine (Fraser et al, 1997a) . These results suggest that Gln-FPP can bind to FPP-specific sites, thus preventing FPP from binding to cells and eliciting a response. Consistent with these results, the presence of 200 nM Gln-FPP along with 100 nM FPP completely inhibited FPP's stimulation of fertilizing ability in vitro ( Figure 2B ; Fraser et al, 1997a) . Finally, Gln-FPP was able to block FPP's inhibition of spontaneous acrosome reactions in capacitated suspensions; in the presence of Gln-FPP + FPP, acrosome loss was as high as in control suspensions with no peptide added (Fraser et al, 1997a) . Gln-FPP may be an intermediate peptide in the FPP biosynthetic pathway and has been identified in human seminal plasma. Recent evidence indicates that the concentration of neutral FPP-related peptides (which could include Gln-FPP) may increase and that of FPP decrease in abundance with the onset of benign prostatic hyperplasia . Our recent results suggest that such changes in the peptide profile found in seminal plasma could compromise fertility in vivo.
FPP and TCP-11
The mouse /-complex, located on chromosome 17, is known to contain genes affecting male but not female fertility (Bennett, 1975; Silver, 1985) . Although male mice with one chromosome 17 carrying the /-complex produce equal numbers of wild-type and /-chromosome bearing spermatozoa, in many instances up to 95% of their offspring will have been fertilized by a /-chromosome-bearing spermatozoon. A biological basis for this transmission ratio distortion has been unclear until recently. The /-complex gene Tcp-11 is expressed only in the testis. The fact that it is transcribed during late spermatogenesis and translated during spermiogenesis (Mazarakis et al, 1991; Hosseini et al, 1994) suggests that it might play a role in sperm function. Very recent studies of TCP-11, the protein coded for by Tcp-11, have indicated a possible mechanism of action via which TCP-11 may modulate sperm fertilizing ability (Fraser et al, 1997b ).
An immunoglobulin G (IgG) fraction was purified from polyclonal anti-TCP-11 antiserum and then Fab fragments were prepared. Western blotting and immunolocalization performed using the purified IgG confirmed the presence of TCP-11 in both the heads and flagella of mature epididymal spermatozoa. TCP-11 was localized to the sperm surface, on the acrosomal cap of acrosome-intact but not acrosome-reacted cells and on the flagellum, particularly the principal piece. Incubation of epididymal mouse sperm suspensions in the presence of Fab fragments resulted in the stimulation of capacitation when assessed with CTC at 30 min and the inhibition of spontaneous acrosome loss when assessed at 120 min ( Figure 3A) . IVF experiments indicated that Fab-treated suspensions were more fertile than untreated controls when tested at 30 min and were still highly fertile at 120 min, despite inhibition of the spontaneous acrosome reaction ( Figure 3B ; Fraser et al, 1997b) . As these results were so similar to those obtained with FPP and adenosine, experiments using different combinations of Fab fragments, FPP and adenosine were performed. Results indicated that the Fab fragments appear to act at the same site as FPP: Fab + FPP was no more stimulatory than either used individually, but Fab + adenosine was more stimulatory than individual treatments. Furthermore, Gln-FPP was able to inhibit responses to Fab fragments in a concentration-dependent manner.
From these results, it was concluded that the anti-TCP-11 Fab fragments, by binding to TCP-11 on the sperm surface, act as an agonist to modulate a signal transduction pathway somehow linked to TCP-11. Given that Fab fragments and FPP appear to work at the same site, one distinct from the adenosine site, we have suggested that TCP-11 may be the receptor for FPP and that it may modulate the adenylate cyclase/cAMP pathway (Fraser et al, 1997b) . Very recent studies provide some confirmation of these hypotheses: both Gln-FPP and Fab fragments can significantly inhibit specific binding of [ 3 H]-FPP to mouse sperm membranes and FPP significantly stimulates adenylate cyclase production of cAMP in both sperm membranes, and intact, permeabilized sperm preparations live cells (Adeoya-Osiguwa et al, 1998) . 
FPP, TCP-11 and regulation of sperm function
Acrosome-reacted spermatozoa, even if highly motile, are unable to fertilize zona-intact oocytes (Yanagimachi, 1994) . The ability of FPP and TCP-11 to stimulate capacitation and then inhibit spontaneous acrosome loss could provide a very important endogenous mechanism for maximizing the numbers of capacitated but still acrosome-intact spermatozoa that reach the site of fertilization in the female reproductive tract. A human homologue of Tcp-11 has been identified (Ragoussis et al, 1992) , suggesting that TCP-11 could play a role in modulating human, as well as mouse, sperm function. It is plausible that subfertility in vivo could result from defects or alterations in FPP and/or TCP-11, e.g. reduced concentrations of FPP in seminal plasma, increased concentrations of less bioactive FPP-related peptides (Gln-FPP) due to prostatic malfunction and alterations in the structure of TCP-11, the putative receptor for FPP.
In future, it may prove feasible to use FPP in a therapeutic way, either by adding it to prepared spermatozoa just prior to intrauterine insemination or to sperm suspensions used for human IVF. The fact that FPP accelerates sperm capacitation might, in some instances, reduce the incidence of delayed fertilization which in turn results in embyos with a low chance of implanting successfully.
